Bimatoprost 0.01% or 0.03% After Latanoprost 0.005% Treatment in Glaucoma or Ocular Hypertension: Two Randomized 12-Week Trials
Narrative Responses:
Purpose
To evaluate the intraocular pressure (IOP)–lowering efficacy and safety of monotherapy with bimatoprost 0.01% or 0.03% in patients treated with latanoprost 0.005% monotherapy who require additional IOP lowering for their ocular hypertension (OHT) or open angle glaucoma (OAG).
Methods
Two prospective, investigator-masked, randomized, parallel-group, multicenter studies enrolled patients with OHT or OAG who had baseline IOP of ≥20 mm Hg after ≥30 days of latanoprost 0.005% monotherapy. Following baseline measurements, patients discontinued latanoprost and were randomized to 12 weeks of study treatment (bimatoprost 0.01% QD or bimatoprost 0.01% QD plus brimonidine 0.1% TID in Study 1; bimatoprost 0.03% QD or bimatoprost 0.03% QD plus fixed-combination brimonidine 0.2%/timolol 0.5% BID in Study 2). Patient evaluations at weeks 4 and 12 included IOP and safety assessments.
Results
Primary and secondary efficacy endpoints including IOP and change from baseline IOP (at 8 am, 10 am, and 4 pm) at week 12 will be reported, as well as safety measures and adverse events for the study arms randomized to monotherapy (bimatoprost 0.01% or bimatoprost 0.03%).
Conclusion
These studies were designed to evaluate alternative monotherapies for patients who do not meet target IOP with latanoprost 0.005% alone.